IPSCNasdaq

Century Therapeutics, Inc.

Healthcare·Oncology·Phase 1·Philadelphia, PA, United States
OncologyImmunologyDermatologyNephrology

Century Therapeutics, Inc. (IPSC): 6 pipeline candidates · ~16 mo cash runway · 3 clinical trials. Updated within the last hour.

5.6/10

BioSniper Score

5-factor signal · derived from public data

Cash Runway4.4

15.9 months

Financial Health8.9

D/E 0.23 · 7% dilution

Pipeline Maturity4.0

Lead: Phase 1

Pipeline Breadth9.8

6 candidates

Catalyst MomentumN/A

N/A

Insider Signal0.9

1 buy · 8 sells (180d)

A transparent, data-derived signal for Century Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$404.9M

Cash

$53.8M

Quarterly Burn

$25.3M

Runway

15.9 mo

Revenue

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Oct 2027
Today~17 mo out
Catalyst within runway

Pipeline (6 candidates)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

69

Total value held

$228.7M

HolderSharesValue
ra capital management, l.p.17,754,430$40.1M
vanguard capital management llc11,372,408$25.7M
deep track capital, lp9,487,745$21.4M
commodore capital lp8,695,652$19.7M
rtw investments, lp8,695,652$19.7M
woodline partners lp6,086,956$13.8M
balyasny asset management l.p.5,017,733$11.3M
millennium management llc4,667,063$10.5M
spruce street capital lp4,059,054$9.2M
adage capital partners gp, l.l.c.3,789,538$8.6M

Showing top 10 of 69 institutional holders of Century Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

3 clinical trials·CEO: Dr. Brent Pfeiffenberger M.B.A., Pharm.D.

Frequently asked questions

How many drug candidates are in Century Therapeutics, Inc.'s pipeline?

Century Therapeutics, Inc. (IPSC) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is Century Therapeutics, Inc.'s lead drug candidate?

Century Therapeutics, Inc.'s most advanced tracked candidate is cnty-101 (Phase 1) for Systemic Lupus Erythematosus; R/R CD19-Positive B-Cell Malignancies.

What is Century Therapeutics, Inc.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, Century Therapeutics, Inc. has approximately 15.9 months of cash runway.

What is Century Therapeutics, Inc.'s market capitalization?

Century Therapeutics, Inc.'s market capitalization is approximately $404.9M.

Who is the CEO of Century Therapeutics, Inc.?

Dr. Brent Pfeiffenberger M.B.A., Pharm.D. is the chief executive officer of Century Therapeutics, Inc. (IPSC).

Get the full picture on Century Therapeutics, Inc.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.